Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Jun;51(6):1312–1324. doi: 10.1194/jlr.M001586

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2010 by the American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

Fig. 4. — Characterization of the HA-FoxO4 UL1 lipid. A: TLC plate autoradiographs of lipid extracts from Puro (P) and HA-FoxO4 (F) fibroblasts either untreated (Cntrl) or pretreated with 10 μM cytochalasin B (Cyt B), 50 μM LY294002 (LY), 50 μM PD 98059 (PD), 0.1 μM rapamycin (Rapa), 10 μM cerulenin (Cer), 20 μg/ml lovastatin (Lova), 5 μM H89, or 20 μM compound C (CpdC) prior to ¹⁴C-acetate labeling. Lipids are labeled as cholesterol (chol) and the FoxO4 unknown lipid as UL1. Each lane represents a lipid extract from two combined wells of a 24-well plate. Inhibition of cholesterol and UL1 are seen with lovastatin treatment. B: TLC plate autoradiograph of lipid extracts from ¹⁴C-labeled Puro and HA-FoxO4 cells treated with two different concentrations of the HMG-CoA reductase inhibitor lovastatin (Lova). C: GC and elution times of blank, Puro, and HA-FoxO4 lipid extracts. D: MS fingerprint of UL1, which consists of lanost-8-en-3-ol (3β), commonly called DHL.